Contribute Try STAT+ Today

Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. As you know, a prescription is not required. So feel free to indulge as you attack the laundry list of online meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day, and, as always, do drop us a line when you hear something interesting. …

Pfizer (PFE) has ramped up production of its Covid-19 vaccine and expects to have delivered a total of 300 million doses to the U.S. two weeks early, in July, CNBC tells us. The drug maker expects to deliver 10% more doses to the U.S. by the end of May than it had previously agreed to — up to 220 million from 200 million. The announcement came as dozens of states temporarily stopped administering the Johnson & Johnson (JNJ) single-dose Covid vaccine following a Food and Drug Administration advisory.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.